Skip to main content

Table 1 Clinical and treatment characteristics of the patients

From: Long-term oncologic outcomes of radiotherapy combined with maximal androgen blockade for localized, high-risk prostate cancer

  Median Range
Age at diagnosis (years) 70 58~81
Gland volume (mL) 33.4 27~62
Follow-up (months) 90 12~186
  Count Percentage (%)
Clinical stage
 T2b 23 7.2
 T2c 167 52.2
 T3a 82 25.6
 T3b 48 15
Gleason score
 ≤6 3 0.9
 7 11 3.4
 ≥8 306 95.6
PSA at diagnosis (ng/mL)
 ≤10 35 10.9
 10~20 49 15.3
 ≥20 236 73.8
Memorial Sloan-Kettering risk classification
 2~3 IS 71 22.2
 1 HS 106 33.1
 2~3 HS 143 44.7
MAB
 Continuous 184 57.5
 Intermittent 136 42.5
PPB
 Yes 203 63.4
 No 117 36.6
PSA nadir (ng/mL)
 ≤1.0 241 75.3
 >1.0 79 24.7
Time to PSA nadir (months)
 ≤3 207 64.7
 >3 113 35.3
PSA doubling time (months)
 ≤12 46 14.4
 >12 274 85.6
PSA decrease (%)
 <90 71 22.2
 ≥90 249 77.8
  1. MAB Maximal Androgen Blockade; PPB Permanent Prostate Brachytherapy; IS intermediate-Risk Standard; HS High-Risk Standard